Drug – bio-affecting and body treating compositions – Designated organic nonactive ingredient containing other... – Aftertreated solid synthetic organic polymer
Patent
1987-08-05
1991-01-22
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic nonactive ingredient containing other...
Aftertreated solid synthetic organic polymer
514788, 514832, 424 5, A61K 4700
Patent
active
049871544
ABSTRACT:
An up to 125% fluorocarbon emulsion for use in or with animal bodies and organs thereof, maintains emulsion stability through normal sterilization procedures with selective osmotic and buffering agents, maintains the emulsion at within predetermined osmolarity levels and, when desired, free of excessive calcium precipitation, reduces in vivo and in vitro red blood cell injury, reduces adverse anemia effects, reduces viscosity and reduces the rate of oxidation, and tends to equilibrate its distribution in major body organs thereby reducing toxicity. The osmotic agents may buffer and may provide nutrient in the form of sugars. The osmotic and buffering agents can comprise, selectively, hexahydric alcohols, namely mannitol and sorbitol; certain sugars, namely glucose, mannose and fructose; along with buffering agents that will affect osmolarity including imidazole, tris(hydroxymethyl)aminomethane, sodium chloride, sodium bicarbonate, monobasic potassium phosphate, dibasic potassium phosphate, calcium chloride, magnesium sulfate, monobasic sodium phosphate, dibasic sodium phosphate or combinations of them. The emulsion may include tocopherol. A method of emulsifying the fluorocarbon includes forced flow impingement under pressure after mixing the fluorocarbon into the discontinuous phase. The fluorocarbon emulsion can be used to deliver drugs and medicines soluble in, or transportable by the emulsion.
REFERENCES:
patent: 3818229 (1974-06-01), Long, Jr.
patent: 3962439 (1976-06-01), Yokoyama et al.
patent: 3975512 (1976-08-01), Long
patent: 4073879 (1978-02-01), Long, Jr.
patent: 4105798 (1978-08-01), Moore et al.
patent: 4146499 (1979-03-01), Rosano
patent: 4343797 (1982-08-01), Ecanow
patent: 4397870 (1983-08-01), Sloviter
patent: 4423077 (1983-12-01), Sloviter
patent: 4439424 (1984-03-01), Ecanow
patent: 4451251 (1984-05-01), Osterholm
patent: 4497829 (1985-02-01), Sloviter
patent: 4605786 (1986-08-01), Yokoyama et al.
patent: 4613708 (1986-09-01), Riess et al.
patent: 4640833 (1987-02-01), Tamborski et al.
patent: 4654337 (1987-03-01), Yokoyama et al.
patent: 4895876 (1990-01-01), Schweighardt et al.
Reiss, Jean G.; Artificial Organs 8:34-56 (1984).
Geyer, R., "Perfluorocarbon Blood Substitutes", Intl. Symp. on Artificial Blood Substitutes, Bari, Italy: Jun. 19-20, (1987), pp. 45-67.
Persico, D. et al., J. Org. Chem. 50:5156-5159 (1985).
Sharts, C. and H. Reese, The Solubility of Oxygen in Aqueous Fluorocarbon Emulsions, J. Fluorine Chemistry 11:637-641 (1978).
Riess, J., International Symposium on Blood Substitutes, Bari, Italy: Jun. 19-20, 1987, Proceedings pp. 135-166.
Davis, S.; Advances in Clinical Nutrition, 19:213-239 (1982).
Yokoyama, K. et al., Fed. Proc. 34(6) 1478-1483 (1975).
Steiner, M. and J. Anastasi, Vitamin E: An Inhibitor of the Platelet Release Function, J. Clinical Invest. 57:732-737 (1976).
Pandolfe, W. D. and R. R. Kinney, National Meeting of the American Institute of Chemical Engineers, Denver, Colo., Aug. 29, 1983.
Gould, S. et al., The Journal of Trauma 23(8): 720-724 (1983).
Moss, G. Polyhemoglobin and Fluorocarbon as Blood Substitutes, Biomaterials, Artificial Cells, and Artificial Organs 15(2): 333-336 (1987).
Geyer, R., "Perfluorocarbons as Oxygen Transport Vehicles", Biomaterials Artificial Cell (as above) 15(2): 329-333 (1987).
Burgan, A., D. M. Long et al. (as above) 15(2): 403(1987).
Police, A. M. et al., Critical Care Medicine 13(2): 96-98 (1985).
Nunn, G. R. et al., American J. of Cardiology 52: 203-205 (1983).
Patel, M. et al., Federation Proceedings 29(5): 1740-1745 (1970).
Bose, B. et al., Brain Research 328: 223-231 (1985).
Spears, J. et al., Myocardial Protection with Fluosol-DA During Prolonged Coronary Balloon Occlusion in the Dog, 68 (Supp. III) No. 317, Oct., 1983.
Peck, W. W. et al., Investigative Radiology 19:129 (1984).
Dobben, G. et al., Neuroradiology 6: 17-19 (1973).
Brahme, F. et al., Acta Radiologica, Supplement 347: 459-466 (1975).
Liu, M. S. et al., Myleography with Perfluoroctylbromide: Comparison with Patopaque, Investigative Radiology 11(4): 319-330 91976).
Long, D. M. et al., Efficacy and Toxicity Studies with Radiopaque Perfluorocarbon, Radiology 105(2): 323-332 (1972).
Itoh, Y. et al., Gan To Kagaku Ryoho 1(4): 864-872 (1984).
Rockwell, S., "Perfluorochemical Emulsions as Adjuncts to Radiotherapy", 3rd Biomaterials, etc. 15(2): 430(1987).
Burgan, A. et al., "Acute and Subacute Toxicity of 100% PFOB Emulsion", 5th Annual Mtng. Soc. of Magnetic Resonance in Med. Montreal: Aug. 18-22, 1986.
Long, D. et al., Total Exchange Perfusion, International Symposium Centenary of the Discovery of Fluorine, Paris, Aug. 25-29, 1986.
Long, D. C. et al., Biomaterials, etc. 15(2): 417(1987).
Long, D. M. et al., "Experimental and Clinical Applications of PFOB", same as above 15(2): 418(1987).
Arlen, C., Long, D. et al., same as above 15(2): 431(1987).
"Patent Abstracts of Japan", vol. 10, No. 13 (C-323), [2070], Jan. 18, 1986, p. 44C323 and JP-A-60 166 626 (Midori Juji K.K.), Aug. 29, 1985.
Alliance Pharmaceutical Corp.
Waddell Frederick E.
LandOfFree
Biocompatible, stable and concentrated fluorocarbon emulsions fo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biocompatible, stable and concentrated fluorocarbon emulsions fo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biocompatible, stable and concentrated fluorocarbon emulsions fo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1555117